Head-to-head · WeighScore
Coivas vs Zealthy
The verdict
Coivas takes it — 66.2/100 to 46.7/100.
Coivas grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Coivas is an all-inclusive GLP-1 telehealth service operated by WellVi LLC (d/b/a Coivas) with prescriptions through Arora Health & Aesthetics, LLC.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Coivas | Zealthy |
|---|---|---|
| WeighScore | 66.2/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #197 | #496 |
| Semaglutide | $149/mo (quarterly plan, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $229/mo (quarterly plan, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #197 · C
Strengths
- All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
- Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
- Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
- Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
- Most patients approved in under 2 hours; refund if no provider visit or prescription occurs
Where it loses points
- Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
- Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
- Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
- No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.